Skip to main content
Signal8

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

$BLRXPress releaseApr 28, 2026, 7:00 AM ETRead the release

BioLineRx and partner Hemispherian dosed the first patient in a Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma. The first-in-human trial will enroll up to 30 patients to establish safety and dosing, with Phase 1 data anticipated in the first half of 2027.

Key figures

Drug Name
GLIX1
Phase Of Trial
Phase 1/2a

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.